These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 30479461)

  • 41. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis.
    White ES; Flaherty KR; Carskadon S; Brant A; Iannettoni MD; Yee J; Orringer MB; Arenberg DA
    Clin Cancer Res; 2003 Feb; 9(2):853-60. PubMed ID: 12576459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression and clinical significance of CXC chemokines in the glioblastoma microenvironment.
    Li C; Deng H; Zhou Y; Ye Y; Zhao S; Liang S; Cai S; Lin J; Tang Y; Wu Y
    Life Sci; 2020 Nov; 261():118486. PubMed ID: 32976881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer.
    Verbeke H; Geboes K; Van Damme J; Struyf S
    Biochim Biophys Acta; 2012 Jan; 1825(1):117-29. PubMed ID: 22079531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.
    De Divitiis C; Nasti G; Montano M; Fisichella R; Iaffaioli RV; Berretta M
    World J Gastroenterol; 2014 Nov; 20(41):15049-59. PubMed ID: 25386053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CXC chemokines and prostate cancer: growth regulators and potential biomarkers.
    Lentsch AB
    Future Oncol; 2006 Oct; 2(5):651-8. PubMed ID: 17026456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.
    Kershaw MH; Wang G; Westwood JA; Pachynski RK; Tiffany HL; Marincola FM; Wang E; Young HA; Murphy PM; Hwu P
    Hum Gene Ther; 2002 Nov; 13(16):1971-80. PubMed ID: 12427307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer.
    Hojo S; Koizumi K; Tsuneyama K; Arita Y; Cui Z; Shinohara K; Minami T; Hashimoto I; Nakayama T; Sakurai H; Takano Y; Yoshie O; Tsukada K; Saiki I
    Cancer Res; 2007 May; 67(10):4725-31. PubMed ID: 17510400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential CXC receptor expression in colorectal carcinomas.
    Rubie C; Kollmar O; Frick VO; Wagner M; Brittner B; Gräber S; Schilling MK
    Scand J Immunol; 2008 Dec; 68(6):635-44. PubMed ID: 18959627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
    Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
    Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CXC receptor and chemokine expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation.
    Barbieri F; Bajetto A; Porcile C; Pattarozzi A; Massa A; Lunardi G; Zona G; Dorcaratto A; Ravetti JL; Spaziante R; Schettini G; Florio T
    Ann N Y Acad Sci; 2006 Dec; 1090():332-43. PubMed ID: 17384278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Role of CXC Chemokines in Cancer Progression.
    Wu T; Yang W; Sun A; Wei Z; Lin Q
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
    Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H
    Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].
    Cohen R; Cervera P; Svrcek M; Dumont C; Garcia ML; Chibaudel B; de Gramont A; Pocard M; Duval A; Fléjou JF; André T
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S72-81. PubMed ID: 26118880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.
    Nguyen MN; Choi TG; Nguyen DT; Kim JH; Jo YH; Shahid M; Akter S; Aryal SN; Yoo JY; Ahn YJ; Cho KM; Lee JS; Choe W; Kang I; Ha J; Kim SS
    Oncotarget; 2015 Oct; 6(31):31674-92. PubMed ID: 26397224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis.
    Tanegashima K; Suzuki K; Nakayama Y; Tsuji K; Shigenaga A; Otaka A; Hara T
    FEBS Lett; 2013 Jun; 587(12):1731-5. PubMed ID: 23669361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutrophil receptors for interleukin-8 and related CXC chemokines.
    Murphy PM
    Semin Hematol; 1997 Oct; 34(4):311-8. PubMed ID: 9347581
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer.
    Wilkinson K; Ng W; Roberts TL; Becker TM; Lim SH; Chua W; Lee CS
    J Clin Pathol; 2021 Oct; 74(10):625-634. PubMed ID: 33753562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of CXC chemokines in A549 airway epithelial cells by trypsin and staphylococcal proteases - a possible route for neutrophilic inflammation in chronic rhinosinusitis.
    Sachse F; von Eiff C; Stoll W; Becker K; Rudack C
    Clin Exp Immunol; 2006 Jun; 144(3):534-42. PubMed ID: 16734624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
    Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E
    Drug Resist Updat; 2011 Dec; 14(6):280-96. PubMed ID: 21955833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.